Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06418880 · ClinicalTrials.gov registry record · Phase 3
Automated Insulin Delivery for Inpatients With Dysglycemia
A Phase 3 study of Type 2 Diabetes and Type 1 Diabetes, sponsored by Emory University.
- Completed
- Registry status
- Phase 3
- Development phase
- 130
- Enrollment target
- 3
- Study locations
NCT06418880: Completed Phase 3 study of Type 2 Diabetes and Type 1 Diabetes, sponsored by Emory University.
NCT06418880 is a Phase 3 study of Type 2 Diabetes and Type 1 Diabetes that has completed, run by Emory University. The registered enrollment target is 130 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06418880, a Phase 3 study of Type 2 Diabetes and Type 1 Diabetes, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 130 participants
- Enrollment target
- 3
- Study locations
Study Summary
This randomized controlled trial will test the efficacy and safety of automated insulin delivery (AID) in hospitalized patients with diabetes (type 1 or type 2) requiring insulin therapy who are admitted to general medical/surgical floors. The main objectives of this study are: * To test the efficacy and safety of AID versus multiple daily insulin injections (MDI) + CGM in the inpatient setting * To determine differences in CGM-derived metrics between AID and MDI plus CGM in the hospital and explore differences in treatment effect according to individual characteristics. Participants will be: * Randomized to AID + remote CGM (intervention) or multiple daily insulin injections (MDI) + CGM (control group) * Followed for a total of 10 days or until hospital discharge (if less than 10 days).
Primary Outcome
This will be captured by the percentage of time spent in glucose target range (TIR 70-180 mg/dl);
Conditions Studied
Interventions
- DEVICE AID system with Remote Real-Time CGM
- COMBINATION_PRODUCT Standard of Care Insulin Therapy + CGM
Study Locations (3)
California
- Stanford University School of Medicine - Stanford
Georgia
- Grady Health System (non-CRN) - Atlanta
Virginia
- University of Virginia School of Medicine - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-01-22 |
| Est. Completion | 2025-10-31 |
| Phase | Phase 3 |
What the finished NCT06418880 record still lists
NCT06418880 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which AID system with Remote Real-Time CGM is the first listed.
NCT06418880 reports a single indexed study location in California, Georgia, Virginia.
Frequently Asked Questions
What is clinical trial NCT06418880 about?
NCT06418880 is a clinical study titled "Automated Insulin Delivery for Inpatients With Dysglycemia". This randomized controlled trial will test the efficacy and safety of automated insulin delivery (AID) in hospitalized patients with diabetes (type 1 or type 2) requiring insulin therapy who are admitted to general medical/surgical floors. The main objectives of this study are: * To test the effic...
What is the current status of trial NCT06418880?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 130 participants. The study started on 2025-01-22. Estimated completion is 2025-10-31.
What conditions does trial NCT06418880 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Type 1 Diabetes.
What interventions are being tested in trial NCT06418880?
The interventions under investigation include: AID system with Remote Real-Time CGM (DEVICE), Standard of Care Insulin Therapy + CGM (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06418880?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06418880 being conducted?
This trial has 3 study locations across California, Georgia, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06418880's enrollment target sits among peer trials
130 127th of 327 higher than 201 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI